2014
DOI: 10.1111/jvh.12206
|View full text |Cite
|
Sign up to set email alerts
|

Retrospective analysis of total direct medical costs associated with hepatitis B patients with oral antiviral versus pegylated interferon therapy in Turkey

Abstract: To explore healthcare costs associated with antiviral treatment of hepatitis B virus (HBV) in Turkey. Research-identified data from a claims processing system for all Turkish health insurance funds were analysed. Adult patients prescribed oral antiviral and pegylated interferon treatment were identified between 1 January 2010 and 31 December 2010. The first prescription date was defined as the index date. Patients were required to have HBV diagnosis within the 6-month pre-index period. Pharmacy, outpatient and… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0
1

Year Published

2014
2014
2019
2019

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 6 publications
(3 citation statements)
references
References 29 publications
0
2
0
1
Order By: Relevance
“…In addition, members of the Turkish Grand National Assembly and the Supreme Court, as well as foreign insurance policy holders and some military personnel, were excluded from the Universal Health Insurance Fund in the SSI; therefore, their data are not in the system. The data have been used in several outcomes research studies [26][27][28][29][30].…”
Section: Methodsmentioning
confidence: 99%
“…In addition, members of the Turkish Grand National Assembly and the Supreme Court, as well as foreign insurance policy holders and some military personnel, were excluded from the Universal Health Insurance Fund in the SSI; therefore, their data are not in the system. The data have been used in several outcomes research studies [26][27][28][29][30].…”
Section: Methodsmentioning
confidence: 99%
“…Progression of HCC from chronic HBV infection usually occurs after two to three decades of disease, and approximately 80% of HCC develop cirrhosis [49]. The economic burden of chronic HBV infection was estimated to be at least $1 billion worldwide and this amount is going to increase [50,51]. Thus, data showing a nearly 50% decline in the numbers of HBV related cirrhosis on waiting lists for LTx is important [52].…”
Section: Trends In the Management Of Chronic Hbv Infection And Cirrhosismentioning
confidence: 99%
“…Gerek hastanelerin yatılı ve ayaktan tedavi birimlerinden elde edilen bilgileri, gerekse eczanelerden gelen verileri birbirlerini destekler, tamamlar nitelikte değerlendirme şansı elde edilmiştir. Bu veri tabanı, belirli sebeplerden ötürü açık veri şeklinde toplumda herkesin ulaşımına açık olmasa da, akademik amaçlı kullanımına izin verilmektedir [7,8].…”
unclassified